Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for

Treatment of Coronary Artery Disease

ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS(R) paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.

"XIENCE V represents an important treatment advance for the estimated 13 million people in the United States suffering from coronary artery disease, and we believe XIENCE V will quickly become the new standard for drug eluting stents given its outstanding clinical results," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Physicians in the United States have been waiting for years to treat their patients with a technology that delivers on the promise of drug eluting stents through both ease of use and excellent clinical performance, and XIENCE V is that technology."

The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. Coronary artery disease occurs when plaque build- up narrows the arteries and reduces blood flow to the heart, which can lead to chest pain or a heart attack.

"XIENCE V was designed to improve safety and efficacy compared to earlier generation stents. The long-term clinical data from two studies performed in both the United States and Europe have now confirmed that XIENCE V is a true next-generation drug elu
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 EnGeneIC, Ltd. , ... treatment of cancer through the targeted delivery of ... together with the Asbestos Disease Research Institute (ADRI), ... South Wales (NSW) Premier,s Award for Excellence in ... the hospitals that will be involved in the ...
(Date:9/15/2014)... researchers led by Northeastern University has developed a ... and a variety of nanocarbon structures in carbon ... scalable, which will allow the researchers to tailor ... in applications ranging from electronic devices to CNT-reinforced ... sports equipment. , Their findings were published in ...
(Date:9/15/2014)... , Sept. 15, 2014 The chemistry, taste, ... climate, says a new article published by the nonprofit American ... PhD, on climate change and its effects on the phytochemical ... an extensive study conducted by Dr. Ahmed in the ... and has implications for the future of medicinal ...
(Date:9/15/2014)... 2014  The second annual International Plasma Awareness ... joint initiative of the Plasma Protein Therapeutics Association ... is designed to: , Raise global awareness ... of plasma donors in saving and improving lives ... rare diseases Member companies are planning ...
Breaking Biology Technology:EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated ... biomaterials including bioimplants processed from human amniotic membrane, ... offering to sell common stock and warrants has ... of the offering on October 30, 2010, through ...
... 5, 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ... engaged Congressman Curt Weldon to assist in supporting ... at a press conference in New York City ... Congressman Weldon will source, evaluate, and ...
... NEW YORK, July 4, 2011 Reportlinker.com ... is available in its catalogue: ... 2011-2021 http://www.reportlinker.com/p0567594/Stem-Cell-Technologies-World-Market-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy ... market develop this decade? Our new report ...
Cached Biology Technology:MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 2Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 3Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 4Stem Cell Technologies: World Market Outlook 2011-2021 2Stem Cell Technologies: World Market Outlook 2011-2021 3Stem Cell Technologies: World Market Outlook 2011-2021 4Stem Cell Technologies: World Market Outlook 2011-2021 5Stem Cell Technologies: World Market Outlook 2011-2021 6Stem Cell Technologies: World Market Outlook 2011-2021 7Stem Cell Technologies: World Market Outlook 2011-2021 8Stem Cell Technologies: World Market Outlook 2011-2021 9Stem Cell Technologies: World Market Outlook 2011-2021 10Stem Cell Technologies: World Market Outlook 2011-2021 11Stem Cell Technologies: World Market Outlook 2011-2021 12
(Date:9/15/2014)... fears that reef biodiversity may not provide the level ... , In an international study published today, Professor David ... Reef Studies (Coral CoE) says we need to identify ... , In coral reefs, just as in any modern-day ... safe and functioning. , Professor Bellwood says, in ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Conditions on Earth for the first 500 million years ... the present day, complete with oceans, continents and active ... geologic eon, called the Hadean, has gained substantial new ... that formed more than 4 billion years ago with ... as a possible geological analog for early Earth. , ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... at Iowa State University have discovered a previously unknown ... Yanhai Yin, an assistant professor in genetics, development and ... called brassinosteroids. The hormone controls the growth of cells. ... how large the plant grows, says Yin. , "Previously, ...
... the oldest synthetic malaria drug, the methylene blue stain, ... a significant contribution to the long-term eradication called for ... study on 160 children with malaria in Burkina Faso, ... have shown that in combination with newer malaria drugs, ...
... Some researchers hope to turn plants into a renewable, ... have to learn how to convert plant biomass into ... efficiently. In new research, chemists have successfully converted cellulose ... the building block called HMF in one step. ...
Cached Biology News:ISU researcher identifies genetic pathway responsible for much of plant growth 2Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... The MitoPT kit is used in conjunction with ... culture and induce apoptosis according to your existing ... as a negative control). Once you have induced ... solution to each population and incubate the cells ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: